Expression of telomerase reverse transcriptase in peripheral T-cell lymphoma

Fumiko Arakawa1 | Hiroaki Miyoshi1 | Noriaki Yoshida1,2 | Kazutaka Nakashima1 | Yosaku Watatani3 | Takuya Furuta1 | Kyohei Yamada1 | Mayuko Moritsubo1 | Mai Takeuchi1 | Eriko Yanagida1 | Yasumasa Shimasaki1 | Kei Kohno1 | Keisuke Kataoka4 | Koichi Ohshima1

1Department of Pathology, School of Medicine, Kurume University, Kurume, Japan
2Department of Clinical Studies, Radiation Effects Research Foundation Hiroshima Laboratory, Hiroshima, Japan
3Departments of Hematology and Rheumatology, Faculty of Medicine, Kindai University Hospital, Osaka, Japan
4Division of Hematology Department of Medicine, School of Medicine, Keio University, Tokyo, Japan

Correspondence
Hiroaki Miyoshi, MD, PhD, Department of Pathology, School of Medicine, Kurume University, 67 Asahimachi, Kurume, Fukuoka 830-0011, Japan. Email: miyoshi_hiroaki@med.kurume-u.ac.jp

Funding information
Grant-in-Aid for Scientific Research of the Ministry of Education, Culture, Sports, Science, and Technology of Japan, Grant/Award Number: 17K08751

Abstract
Telomere length is maintained by the activation of telomerase, which causes continuous cell division and proliferation in many carcinomas. A catalytic reverse transcriptase protein (TERT) encoded by the TERT gene plays a critical role in the activation of telomerase. We performed a molecular and pathological analysis of the TERT against three different peripheral T-cell lymphoma (PTCL) subtypes: PTCL, not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), and adult T-cell leukemia/lymphoma (ATLL). Immunohistochemical analysis demonstrated TERT expression in 31% of AITL, 11% of PTCL-NOS, and 5% of ATLL. Among them, AITL frequently showed high TERT expression with statistical significance. TERT promoter mutation analysis and genomic copy number evaluation were performed. TERT promoter mutation was observed in two cases of PTCL-NOS (2/40) and not in other PTCLs. Genome copy number amplification was detected in 33% of PTCL-NOS, 33% of AITL, and 50% of ATLL cases. We evaluated the relationship between the analyzed TERT genomic abnormalities and protein expression; however, no apparent relationship was observed. Furthermore, immunostaining showed TERT expression in the PTCL cytoplasm, suggesting the existence of mechanisms other than the maintenance of telomere length. Statistical analysis of the effect of TERT expression on the prognosis in PTCL cases revealed that TERT expression tended to have a poor prognosis in PTCL-NOS. Since TERT expression was not an independent factor in multivariate analysis, further research will be needed to clarify the poor prognosis of PTCL-NOS in TERT expression.

KEYWORDS
copy number assay, immunohistochemistry, mutation analysis, peripheral T-cell lymphoma, telomerase reverse transcriptase

Hiroaki Miyoshi and Noriaki Yoshida contributed equally to this study.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
1 | INTRODUCTION

A telomere is located at the ends of the chromosome, and its length decreases with each cell division.\(^1\) Telomere shortening blocks further cell division and induces cellular senescence in normal cells.\(^2\) Telomerase prolongs telomeres by synthesizing terminal telomeric repeats, which maintains cell division ability. There are two important telomerase components: the telomerase RNA that works as an RNA template and the catalytic reverse transcriptase protein (TERT). Cancer cells are characterized by continuous cell division and it is known that the telomere length is stabilized by telomerase in many malignant tumors.\(^3\) The ectopic expression of TERT causes the immortalization of normal cells in in vitro models.\(^4\) From this standpoint, TERT expression is considered an important factor for carcinogenesis. TERT expression is commonly silenced in somatic cells; however, it is observed during the embryonic period and in some stem cells, especially in cancer cells.\(^5\) Somatic mutations (TERT promoter mutations) are often detected at the proximal promoter site of TERT in cancer cells. These mutations cause deregulation of TERT expression, resulting in overexpression. TERT promoter mutations are frequently observed in malignant melanoma, bladder cancer, renal pelvis cancer, thyroid cancer, hepatocellular carcinoma, and malignant glioblastoma. Moreover, it is rarely identified in lung, breast, colon, and gastric cancers.\(^2,6,7\) A previous study found that the effect of TERT promoter mutation on the transcriptional regulation varies in each cell differentiation stage, suggesting that the difference in TERT promoter mutation frequency is responsible for the difference in cell-of-origin of cancer cells.\(^8\)

Non-Hodgkin lymphoma (NHL) is a malignant tumor that arises from B cells or T/NK cells. These immune cells require clonal proliferation of cells that respond to specific antigens as well as cell division. Therefore, in some mature immune cells, the expression of TERT is maintained so that the cells can continuously proliferate.\(^9\) In B-cell lymphoma of NHL, TERT promoter mutations are observed in Mantle cell lymphoma,\(^10\) but are rare in the other subtypes including diffuse large B-cell lymphoma which is the most common type of NHL.\(^11\) In peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), adult T-cell leukemia/lymphoma (ATLL), and angioimmunoblastic T-cell lymphoma (AITL) are common subtypes.\(^12,14\) ATLL is linked to the human T-cell lymphotropic virus type 1 (HTLV-1) infection, where HTLV-1 basic leucine zipper (HBZ) is reported to induce the expression of TERT.\(^15\) However, TERT expression has not been fully investigated in other PTCL disease types.

In this study, we analyzed TERT expression in PTCL-NOS, ATLL, and AITL and attempted to examine genomic abnormalities related to TERT upregulation in these diseases.

2 | MATERIALS AND METHODS

2.1 | Patients

We reviewed 200 PTCL cases composed of 73 PTCL-NOS, 49 AITL, and 78 ATLL. This study included cases from the International Peripheral T-cell and Natural Killer/T cell Lymphoma Study\(^12\) and diagnosed at Kurume University between 2005 and 2019. PTCL-NOS and ATLL cases were included in our previous studies.\(^16–21\) All cases were reviewed by experienced hematopathologists (O. K., M. H.) according to the World Health Organization classification.\(^22\) Clinical information was collected by reviewing the patients’ medical charts. Among the analyzed PTCL-NOS cases in the current study, 27 cases were classified from the presence of genomic alterations in a previous study.\(^23\) The study was approved by the Research Ethics Committee of Kurume University and was conducted in accordance with the Declaration of Helsinki.

2.2 | Morphological evaluation

For morphological and immunohistochemical analyses, a tissue microarray (TMA) slide was created, as previously described.\(^16–18,24\) Briefly, the representative tumor areas were identified on the corresponding hematoxylin- and eosin-stained slides. For every case, one sample with approximately 2–3 mm diameter from the paraffin section was obtained using a tissue microarrayer.

Each sample was investigated for its morphologic characteristics according to our previous study.\(^17\) Neoplastic T cells were detected by assessing morphological findings, including cell size and nuclear atypia. Some evaluated nuclear atypia characteristics include pleomorphic nuclei of varying sizes, large nucleoli, and hyperchromatism with the coarse and irregular distribution.

2.3 | Immunohistochemical analysis

Immunostaining of TERT was performed using rabbit monoclonal to telomerase reverse transcriptase antibody (Y182) (Abcam). This monoclonal antibody was prepared using a synthetic peptide of the human telomerase reverse transcriptase aa1100-1200 (C-terminal) as
an immunogen. The conditions for immunostaining were performed as follows. Antigen retrieval was performed by heat mediation at 95°C for 20 min using a microwave. Samples were incubated with primary antibody (1/100) for 30 min. An undiluted HRP-conjugated goat anti-rabbit IgG polyclonal was used as the secondary antibody. Tumor cells with more than 30% staining were considered positive in the current study. Immunohistochemical investigation of TBX21 (4B10; Abcam) and GATA3 (D13C9; Cell Signaling Technology) was performed for PTCL-NOS. Tumor cells with more than 30% staining were considered positive as in our previous study.24

2.4 | PCR and sequencing for TERT

Among the samples analyzed using TERT immunostaining, purified DNA from 40 PTCL-NOS, 21 AITL, and 10 ATLL cases were subjected to TERT promoter mutation analysis. Each of these DNA samples was extracted from frozen sections.

PCR was performed in the region containing the 5’ upstream position −124 and −146 bp from the ATG start codon, which is a hot spot of TERT promoter mutation. Briefly, PCR conditions were as follows: after the initial denaturation at 95°C for 10 min, 40 cycles of 95°C were performed for 30 s, followed by 65°C for 30 s, and 72°C for 30 s, with a final extension at 72°C for 10 min, using AmpliTaq Gold DNA Polymerase Master Mix 360 (Applied Biosystems). The primer sequences were as follows: sense primer, TERT-P-FW; 5′-cacccgtcctgccccttcaccttcc-3′ and anti-sense primer TERT-P-RV; 5′-ggcttcccacgtgcgcagcagga-3′, as used in a previous study.25 Amplified PCR products were evaluated in 3% agarose gel and visualized using ethidium bromide staining under ultraviolet light. PCR product sizes were 193 bp.

For the amplified PCR product cleanup, DNA was used with ExoSAP-IT or ExoSap-IT Express (Applied Biosystems). Next, Sanger sequencing was conducted to confirm the mutation of the TERT promoter. The direct sequencing reaction was carried out with an ABI Big Dye Terminator v1.1 cycle sequencing kit (Applied Biosystems), cycled at 96°C for 1 min, 25 cycles of 96°C for 10 s, 50°C for 5 s, and 60°C for 4 min. The primer TERT-P-FW was used for the sequence reaction. The resulting products were run on an ABI PRISM 310 or SeqStudio Genetic Analyzer (Applied Biosystems).

2.5 | TaqMan copy number assay for TERT

The copy number of hTERT (Hs03078158.cn) was quantified with TaqMan Copy Number Assays (Applied Biosystems) using the same DNA that was subjected to the sequence analysis above. The human RNase P was used as the TaqMan Reference Copy Number Assay (Applied Biosystems). Quantitative real-time PCR was performed with an ABI 7500 real-time system (Applied Biosystems) using TaqMan Genotyping Master Mix (Applied Biosystems). The relative copy number of hTERT was calculated with CopyCaller v2.1 software (Applied Biosystems) using the \( \Delta \Delta \text{Ct} \) method. A relative copy number >2 was defined as the TERT copy number gain.

2.6 | Statistical analysis

Frequencies of TERT expression were evaluated using Fisher’s exact test or the test with Bonferroni correlation when needed. The overall survival (OS) curves were calculated using the Kaplan–Meier method. The endpoints of OS were defined as the time of relapse and death. A log-rank test was used to compare survival curves. A Cox proportional hazards model was used in the multivariate analysis. Statistical analyses in this study were carried out with JMP, version 13 (SAS Institute). A p-value of <0.05 indicated statistical significance.

3 | RESULTS

3.1 | TERT expression, gene mutation, and copy number variations analysis in PTCL

We first assessed the TERT expression by immunostaining of each PTCL subtype. Expression of TERT was observed in 8 PTCL-NOS (11%), 15 AITL (31%), and 4 ATLL (5%) cases (Figure 1A,C). The expression was localized in the cytoplasm in all cases (Figure 1B). Gene mutation analysis of the TERT promoter region was performed to evaluate the expression mechanism of TERT (40 PTCL-NOS, 21 AITL, and 10 ATLL cases). In this analysis, mutations at the TERT promoter site were found in two PTCL-NOS cases, but not in other cases. Among the identified mutations, one was −146 bp upstream (−146 C > T) and the other was −112 bp upstream (−112 C > T) from the ATG start site. In addition to somatic mutations, the copy number gain of TERT has also been suggested to be involved in the expression of several tumors.26 We, therefore, carried out a copy number assay for TERT in this study. The TERT copy number gain was detected in 13 PTCL-NOS (33%), 7 AITL (33%), and 5 ATLL (50%) cases (Figure 1C). Two PTCL-NOS cases with a TERT promoter mutation simultaneously obtained a copy number gain. Therefore, TERT copy
number gain was observed in a total of 13 PTCL-NOS (33%), 7 AITL (33%), and 5 ATLL (50%) cases.

3.2 | Relationship between the TERT expression and genomic abnormalities

We evaluated the relationship between the TERT expression and genomic abnormalities from PTCL analyses (Figure 1C). In this study, the TERT promoter mutations were present in 2 cases of PTCL-NOS (Figure 1B). One case had the −146 C > T mutation and was positive for TERT protein. This gene mutation has been shown to enhance TERT promoter activity.27,28 Moreover, for −112 C > T, a novel mutation, TERT expression was not observed in the PTCL-NOS case. Therefore, it is thought that the mutation did not contribute to the TERT expression. We evaluated TERT expression frequency based on genomic abnormalities (Figure 1D). Although the number of cases used for genomic abnormality analysis was small in ATLL, no clear relationship was found between the presence or absence of genomic abnormality and TERT expression (Figure 1D).

3.3 | TERT expression in subtypes of PTCL-NOS

Several studies including us have classified PTCL-NOS, which is a heterogeneous disease, into subtypes based on molecular and pathological findings.29 We evaluated TERT expression in the subtypes of PTCL-NOS. Molecular analysis classified PTCL-NOS cases into three groups; those with TFH-related alterations (TET2, RHODA G17V, and IDH2) (Group 1), those with TP53/CDKN2A alterations (Group 2) and, those lacking any of the above alterations (Group 3).23 Among the analyzed PTCL-NOS cases in the current study, 27 cases were classified from the molecular aspects. Twelve (45%) cases were classified as Group 1, nine (33%) cases were as Group 2, and six (22%) were as Group 3 (Figure 1C). Among the Groups, Group 3 showed a high frequency of TERT expression (33%) compared with the other Groups (Group 1; 17% and Group 2; 11%) (Figure 1C) though the difference was not significant (p = 0.676). Additionally, PTCL-NOS is divided into three subtypes based on the presence of key transcriptional factors for T-cells; TBX21 and GATA3 and related proteins by immunohistochemistry.30 We checked the...
association between the transcriptional factors and TERT expressions (Table 1). The analysis found that TERT expression was associated with the absence of GATA3 expression ($p = 0.041$) though the expression was not with TBX21 expression ($p = 0.669$).

### 3.4 Clinical significance of TERT expression

TERT promoter mutations and their expression have been reported as prognostic factors in several tumors, including glioblastoma and malignant melanoma.\(^{31-34}\) Since the TERT expression in PTCL is thought to be controlled by various mechanisms other than the promoter site mutations, we investigated the clinical impact of TERT protein expression in our PTCL cases (Figure 2). In PTCL-NOS, TERT expression was associated with a poor prognosis and a statistical significance (Median overall survival, TERT-positive 6.2 Months, 95% confidence interval [CI] 0.5–51.1, TERT-negative 45 months, 95% CI 22.3–209.1; $p = 0.0475$, Log-rank test). This trend was not observed for AITL and ATLL. Since the international prognostic index (IPI), presence of B-symptoms, and the expression of cytotoxic molecules are currently recognized as prognostic factors in PTCL-NOS,\(^{35-38}\) we simultaneously integrated these known prognostic markers and TERT expression in a multivariate analysis to show the risk of each factor (Table 2). The analysis found that IPI was an independent poor prognostic factor; however, other factors, including TERT expression, were not independent prognostic factors.

### 4 Discussion

In this study, we analyzed the TERT expression in PTCL and its genomic abnormalities. The expression of TERT protein was most frequently observed in AITL among the PTCL cases examined. We also found that TERT promoter mutations were rare in PTCL. Regarding TERT promoter mutations, it is known that $-146 \ C > T$ mutation enhances TERT promoter activity by taking the TTCCGG sequence.\(^{27,28}\) Indeed, the PTCL-NOS case with the $-146 \ C > T$ mutation was positive for TERT protein. In the other PTCL-NOS case, $-112 \ C > T$ mutation did not result in the TTCCGG sequence. Therefore, it is thought that the mutation did not contribute to the TERT expression.

Cases with a copy number gain of TERT were not consistently positive for TERT protein (Figure 1C). This finding is in line with previous results of a part of cancers.\(^{39}\) A possible explanation for the lack of association is that the probes for TERT copy number analysis in the studies including the current study do not cover the entire TERT gene. Additionally, TERT expression has been known to be regulated by several mechanisms including transcription, splicing, epigenetics,\(^{40}\) and this tight regulation mechanism may be also related to the lack of association between copy number gain and the expression in TERT.

In normal T cells, it has been reported that the telomere length is shorter, and the frequency of cell division is lower in memory T-cells than in naïve T cells.\(^{41}\) AITL, which showed a high frequency of the TERT expression in the current study, is considered a tumor derived from follicular helper T-cells.\(^{42}\) One of the pathological characteristics of AITL is the presence of the Epstein-Barr virus (EBV) infection in non-tumor cells. EBV-reactive peripheral CD8-positive T-cells have been reported to express telomerase,\(^{42}\) and a similar mechanism may exist in AITL. A previous study showed that T-cells from both young and old donors can re-express telomerase after anti-CD3/CD28 stimulation, suggesting the importance of T-cell receptor (TCR) signaling in the maintenance of telomeres in T-cells.\(^{43}\) In addition, TERT phosphorylated by the NF-κB activation appears to translocate from the cytoplasm into the nucleus of normal T-cells.\(^{44}\) All positive cases in this analysis were also positive in the cytoplasm, and no translocation into the nucleus was observed. Large-scale genomic aberration analysis has revealed that the activation of TCR signaling plays a critical role in the pathophysiology of PTCL.\(^{23,45-48}\) RHOA G17V mutation was found in approximately 70% of AITL cases, and the mutation causes the activation of TCR signaling.\(^{49,50}\) Therefore, it is speculated that the analyzed AITL cases also have the activation of the TCR signaling pathway, but TERT was found in the cytoplasm. These findings suggest that TERT plays different roles in PTCL other than the maintenance of telomere length. In addition to telomere DNA synthesis activity, TERT can play as an RNA-dependent RNA polymerase.\(^{51}\) It is also found that the activity of RNA-dependent RNA polymerase was associated with the maintenance of cancer stem cells\(^{52}\) and that the RNA polymerase can control several gene expressions.\(^{53}\) Furthermore, it is reported that TERT localized in mitochondria shuttled

| TABLE 1 | Statistical association of TERT protein with T-bet/ TBX21 and GATA3 in PTCL-NOS |
|----------|-----------------|-----------------|---|
| T-bet/TBX21 + (8) | TERT – (64) | $p$-value |
| T-bet/TBX21 + (15) | 2 (25.0%) | 13 (20.3%) | 0.669 |
| T-bet/TBX21 - (57) | 6 (75.0%) | 51 (79.7%) |
| GATA3 + (58) | 4 (50.0%) | 54 (84.4%) | 0.041 |
| GATA3 – (14) | 4 (50.0%) | 10 (15.6%) |
from the nucleus under oxidative stress, and it protects mitochondrial function. This prevents DNA damage by the reduction of reactive oxygen stress from mitochondria and it is considered that this mechanism is involved in resistance to chemotherapies in cancer cells. As we found that TERT expression in PTCL was mainly found in the cytoplasm, we speculate that those mechanisms contribute to the pathogenesis of PTCL that is recognized as a dismal disease.

In this analysis, the TERT expression was observed in 11% of PTCL-NOS. PTCL-NOS is a heterogeneous disease that does not belong to other PTCLs. Some PTCL-NOS cases have been shown to be AITL-like diseases based on cell surface markers and genomic mutations. PTCL-NOS expressing the AITL surface antigen markers PD-1, CD10, CXCL13, and BCL6 were excluded in this analysis and further analysis of PTCL-NOS cases and other types of PTCL may precisely elucidate the significance of the TERT expression in PTCL.

In ATLL, HBZ of HTLV-1 and JunD has been reported to enhance TERT transcriptional activity. Moreover, Tax, which is another viral protein of HTLV-1, suppresses TERT along with T-cell acute lymphoblastic leukemia 1 (TAL1), which causes genomic instability in HTLV-1-infected cells. Although Tax is silenced by methylation in many ATLLs, HBZ expression is observed in such ATLLs. We previously analyzed the existence of HBZ and Tax in ATLL by RNA in situ. Although some of the cases analyzed in this study (42 ATLL cases) were also included in the previous study, we could not assess the relationship between TERT and HBZ expression due to the limited number of TERT positive cases (two cases) in ATLL (data not shown). The fact that the expression of HBZ was observed in all 42 cases supports that the expression of TERT in ATLL may also be caused and maintained by other mechanisms.

The molecular classification found that there was no clear association between TERT expression and the molecular subtype in PTCL-NOS though the analyzed cases were limited. Regarding the cell-of-origin, we analyzed the expressions of TBX21 and GATA3. We found that TERT expression was associated with the absence of GATA3 expression though the expression was not with TBX21 expression, suggesting that the cases with TERT expression are not classified as PTCL-GATA3 group at least.

### Table 2: Multivariate analysis for overall survival in patients with PTCL-NOS

|                        | HR   | 95% CI     | p-value |
|------------------------|------|------------|---------|
| IPI >1                 | 3.53 | 1.13–10.96 | 0.0294  |
| Expression of cytotoxic molecules | 0.74 | 0.23–2.36  | 0.614   |
| Presence of B-symptom  | 1.09 | 0.34–3.49  | 0.884   |
| Presence of TERT expression | 1.7  | 0.29–9.97  | 0.555   |

Abbreviations: CI, confidence interval; HR, hazard ratio; IPI, international prognostic index; PTCL-NOS, peripheral T-cell lymphoma, not otherwise specified.

### Figure 2

Overall survival of the cases with or without a TERT expression. A log-rank test was used to compare survival curves. (A) PTCL-NOS; (B) AITL; (C) ATLL.
Although this study showed the significance of TERT in PTCLs, there are some limitations in this study. First, this study includes only three subtypes of PTCL. Other subtypes including ALCL including nodular PTCL with Tfh phenotypes should be investigated in the future to clarify the role of TERT in PTCLs. Second, the validity of the cut-off value at 30% for IHC may improve the prognosis. Third, a validation cohort using more samples will be required to show the significance.

In this study, the TERT expression was associated with a poor prognosis in PTCL-NOS but was confounded with other factors in the risk analysis. Recently, small-molecule inhibitors for TERT or telomerase RNA have been developed and showed a response in several cancers.\(^\text{57}\) Such inhibitors may also be effective in TERT-positive PTCL and may improve the prognosis.

**ACKNOWLEDGMENTS**

The authors would like to thank Dr. Masao Seto for critical discussions and constructive suggestions. This study was supported by the Grant-in-Aid for Scientific Research of the Ministry of Education, Culture, Sports, Science, and Technology of Japan (MEXT KAKENHI Grant Number 17K08751).

**CONFLICT OF INTEREST**

The authors declare no potential conflicts of interest.

**AUTHOR CONTRIBUTION**

Conception and design: FA and NY. Acquisition of data (acquired and managed patients, etc.): HM, MM, MT, EY, KK, YS, and KO. Analysis and interpretation of data (e.g., immunohistochemistry, sequence analysis, statistical analysis, computational analysis): FA, HM, KN, TF, and KY. Analysis of molecular subclass for PTCL-NOS: YW and KK. Writing and review of the manuscript: FA, NY, and HM. Study supervision: HM and KO.

**ETHICAL APPROVAL STATEMENT**

The study was approved by the Research Ethics Committee of Kurume University and was conducted in accordance with the Declaration of Helsinki.

**ORCID**

Fumiko Arakawa  
https://orcid.org/0000-0003-2998-056X  
Hiroaki Miyoshi  
https://orcid.org/0000-0002-2356-3725  
Noriaki Yoshida  
https://orcid.org/0000-0001-7001-0106  
Mayuko Moritsubo  
https://orcid.org/0000-0002-3382-0473

**REFERENCES**

1. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. *Nature*. 1990;345:458-460.
2. Shay JW. Role of telomeres and telomerase in aging and cancer. *Cancer Discov.* 2016;6:584-593.
3. Kim N, Piatyszek M, Prowse K, et al. Specific association of human telomerase activity with immortal cells and cancer. *Science*. 1994;266:2011-2015.
4. Morales CP, Holt SE, Ouellette M, et al. Absence of cancer-associated changes in human fibroblasts immortalized with telomerase. *Nat Genet*. 1999;21:115-118.
5. Shay JW, Wright WE. Telomerase therapeutics for cancer: challenges and new directions. *Nat Rev Drug Discov*. 2006;5:577-584.
6. Vinagre J, Almeida A, Pópulo H, et al. Frequency of TERT promoter mutations in human cancers. *Nat Commun*. 2013;4:2185.
7. Liu T, Yuan X, Xu D. Cancer-specific telomerase reverse transcriptase (TERT) promoter mutations: biological and clinical implications. *Genes (Basel)*. 2016;7(7):38.
8. Chiba K, Johnson JZ, Vogan JM, Wagner T, Boyle JM, Hockemeyer D. Cancer-associated TERT promoter mutations abrogate telomerase silencing. *Elife*. 2015;4.
9. Hodes RJ, Hathcock KS, Weng NP. Telomeres in T and B cells. *Nat Rev Immunol*. 2002;2:699-706.
10. Panero J, Alves-Paiva RM, Roisman A, et al. Acquired TERT promoter mutations stimulate TERT transcription in mantle cell lymphoma. *Am J Hematol*. 2016;91:481-485.
11. Lam G, Xian RR, Li Y, Burns KH, Beemon KL. Lack of TERT promoter mutations in human B-cell non-Hodgkin lymphoma. *Genes (Basel)*. 2016;7.
12. Vose J, Armitage J, Weisenburger D; International TCLP. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. *J Clin Oncol*. 2008;26:4124-4130.
13. Chihara D, Ito H, Matsuda T, et al. Differences in incidence and trends of haematological malignancies in Japan and the United States. *Br J Haematol*. 2014;164:536-545.
14. Muto R, Miyoshi H, Sato K, et al. Epidemiology and secular trends of malignant lymphoma in Japan: analysis of 9426 cases according to the world health organization classification. *Cancer Med*. 2018;7(11):5843-5858.
15. Kuhlmann AS, Villaudy J, Gazzolo L, Castellazzi M, Mesnard JM, Duc DM. HTLV-1 HBZ cooperates with JunD to enhance transcription of the human telomerase reverse transcriptase gene (hTERT). *Retrovirology*. 2007;4:92.
16. Miyoshi H, Kiyasu J, Kato T, et al. PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma. *Blood*. 2016;128:1374-1381.
17. Kato T, Miyoshi H, Kobayashi S, et al. Clinicopathological analysis in PTCL-NOS with CADM1 expression. *Virchows Arch*. 2017;471:659-666.
18. Takeuchi M, Miyoshi H, Asano N, et al. Human leukocyte antigen class II expression is a good prognostic factor in adult T-cell leukemia/lymphoma. *Haematologica*. 2019;104:1626-1632.
19. Moritsubo M, Miyoshi H, Matsuda K, et al. TACC3 expression as a prognostic factor in aggressive types of adult T-cell leukemia/lymphoma patients. *Int J Lab Hematol*. 2020;42:842-848.
20. Yanagida E, Miyoshi H, Takeuchi M, et al. Clinicopathological analysis of immunohistochemical expression of CD47 and SIRPalpha in adult T-cell leukemia/lymphoma. *Hematol Oncol*. 2020;38:680-688.
21. Yamada K, Miyoshi H, Yoshida N, et al. Human T-cell lymphotropic virus HBZ and tax mRNA expression are associated with specific clinicopathological features in adult T-cell leukemia/lymphoma. Mod Pathol. 2020;34:314–326.

22. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood. 2016;127:2375-2390.

23. Watatani Y, Sato Y, Miyoshi H, et al. Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling. Leukemia. 2019;33:2867-2883.

24. Yanagida E, Miyoshi H, Kawamoto K, et al. Clinicopathological analysis of immunohistochemical expression of retinoic acid-related orphan receptor-gammaT in peripheral T-cell lymphoma, not otherwise specified. Hum Pathol. 2018;79:86-92.

25. Liu T, Brown TC, Juhlin CC, et al. The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors. Endocr Relat Cancer. 2014;21:427-434.

26. Zhang A, Zheng C, Lindvall C, et al. Frequent amplification of the telomerase reverse transcriptase gene in human tumors. Can Res. 2000;60:6230-6235.

27. Horn S, Figl A, Rachakonda PS, et al. TERT promoter mutations in familial and sporadic melanoma. Science. 2013;339:959-961.

28. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. Highly recurrent TERT promoter mutations in human melanoma. Science. 2013;339:957-959.

29. Yoshida N, Yamada K, Ohshima K. Comprehensive genomic analysis identifying heterogeneity in peripheral T-cell lymphoma. Cancer Sci. 2021;112:1339-1347.

30. Amador C, Greiner TC, Heavican TB, et al. Reproducing the molecular subclassification of peripheral T-cell lymphoma-NOJs by immunohistochemistry. Blood. 2019;134:2159-2170.

31. Li C, Wu S, Wang H, et al. The C228T mutation of TERT promoter frequently occurs in bladder cancer stem cells and contributes to tumorigenesis of bladder cancer. Oncotarget. 2015;6:19542-19551.

32. Simon M, Hosen I, Gousias K, et al. TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas. Neuro Oncol. 2015;17:45-52.

33. Liu C, Liu Z, Chen T, Zeng W, Guo Y, Huang T. TERT promoter mutation and its association with clinicopathological features and prognosis of papillary thyroid cancer: a meta-analysis. Sci Rep. 2016;6:36990.

34. Campos MA, Macedo S, Fernandes M, et al. TERT promoter mutations are associated with poor prognosis in cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2019;80(660–669):e666.

35. Asano N, Kinoshita T, Tamaru J-I, et al. Cytotoxic molecule-positive classical Hodgkin's lymphoma: a clinicopathological comparison with cytotoxic molecule-positive peripheral T-cell lymphoma of not otherwise specified type. Haematologica. 2011;96:1636-1643.

36. Kim YR, Kim JS, Kim SJ, et al. Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy. J Hematol Oncol. 2011;4:34.

37. Broussais-Guillaume F, Coso D, Belmeccheri N, et al. Peripheral T-cell lymphomas: analysis of histology, staging and response to treatment of 208 cases at a single institution. Leuk Lymphoma. 2013;54:2392-2398.

38. Chen YP, Jones D, Chen TY, Chang KC. Epstein-Barr virus present in T cells or B cells shows differential effects on hemophagocytic symptoms associated with outcome in T-cell lymphomas. Leuk Lymphoma. 2014;55:2038-2047.

39. Cao Y, Bryan TM, Reddel RR. Increased copy number of the TERT and TERC telomerase subunit genes in cancer cells. Cancer Sci. 2008;99:1092-1099.

40. Dratwa M, Wysoczanska B, Lacina P, Kubik T, Bogunia-Kubik K. TERT-Regulation and roles in cancer formation. Front Immunol. 2020;11:589929.

41. Weng NP, Levine BL, June CH, Hodes RJ. Human naive and memory T lymphocytes differ in telomeric length and replicative potential. Proc Natl Acad Sci USA. 1995;92:11091-11094.

42. Maini MK, Soares MV, Zilch CF, Akbar AN, Beverley PC. Virus-induced CD8+ T cell clonal expansion is associated with telomerase up-regulation and telomere length preservation: a mechanism for escape from replicative senescence. J Immunol. 1999;162:4521-4526.

43. Son NH, Murray S, Yanovski J, Hodes RJ, Weng N. Lineage-specific telomere shortening and unaltered capacity for telomerase expression in human T and B lymphocytes with age. J Immunol. 2000;165:1191-1196.

44. Liu K, Hodes RJ, Weng N. Cutting edge: telomerase activation in human T lymphocytes does not require increase in telomerase reverse transcriptase (hTERT) protein but is associated with hTERT phosphorylation and nuclear translocation. J Immunol. 2001;166:4826-4830.

45. Palomeru T, Couronné L, Khiaobanian H, et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet. 2014;46:166-170.

46. Sakata-Yanagimoto M, Enami T, Yoshida K, et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet. 2014;46:171-175.

47. Yoo HY, Sung MK, Lee SH, et al. A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. Nat Genet. 2014;46:371-375.

48. Kataoka K, Nagata Y, Kitakata A, et al. Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat Genet. 2015;47:1304-1315.

49. Cortes JR, Ambesi-Impiombato A, Couronné L, et al. RHOAG17V Induces T Follicular Helper Cell Specification and Promotes Lymphomagenesis. Cancer Cell. 2018;33(259–273):e257.

50. Ng SY, Brown L, Stevenson K, et al. RHOA G17V is sufficient to induce autoimmunity and promotes T cell lymphomagenesis in mice. Blood. 2018;132(9):935-947.

51. Maida Y, Yasukawa M, Furuiuchi M, et al. An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA. Nature. 2009;461:230-235.

52. Okamoto N, Yasukawa M, Nguyen C, et al. Maintenance of tumor initiating cells of defined genetic composition by nucleostemin. Proc Natl Acad Sci USA. 2011;108:20388-20393.

53. Maida Y, Yasukawa M, Masutomi K. De Novo RNA synthesis by RNA-dependent RNA polymerase activity of telomerase reverse transcriptase. Mol Cell Biol. 2016;36:1248-1259.

54. Lipinska N, Romaniuk A, Paszyl-Jaworska A, Toton E, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish lymphoma registry. Blood. 2014;124:1570-1577.
56. Matsuoka M, Jeang KT. Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy. Oncogene. 2011;30:1379-1389.

57. Jafri MA, Ansari SA, Alqahtani MH, Shay JW. Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies. Genome Med. 2016;8:69.

How to cite this article: Arakawa F, Miyoshi H, Yoshida N, et al. Expression of telomerase reverse transcriptase in peripheral T-cell lymphoma. Cancer Med. 2021;10:6786–6794. https://doi.org/10.1002/cam4.4200